Bender Robert & Associates Summit Therapeutics Inc. Transaction History

Bender Robert & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 13, 2023	BUY	$1.32 - $2.81 $13,200 - $28,100	10,000 Added 71.13%	24,059 $60,000
Q1 2023 Apr 20, 2023	BUY	$1.38 - $5.41 $19,401 - $76,059	14,059 New	14,059 $24,000
Q2 2022 Jul 19, 2022	BUY	$0.92 - $2.38 $12,934 - $33,460	14,059 New	14,059 $14,000
Q2 2021 Jul 16, 2021	SELL	$5.15 - $8.46 $72,403 - $118,939	-14,059 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$5.17 - $11.19 $72,685 - $157,320	14,059 New	14,059 $83,000

192

75.8M

2.01M

2.84M

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.6B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

Stay updated on Bender Robert & Associates with notifications on news.